EGFR and non-small cell lung carcinoma: Over the years, EGFR‐targeted therapies with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib have been developed to greatly improve the outcome of patients with EGFR‐activating mutations in NSCLC.[6] However, most patients eventually develop resistance to these 1st generation TKIs, often carrying EGFR/T790M mutation.[7] Although osimertinib (AZD9291) was developed to address this resistance, new mutations like EGFR/C797S and EGFR/L718Q continue to emerge, highlighting the need for alternative therapeutic strategies to target EGFR signaling in EGFR‐TKI‐resistant NSCLC.[8]